Clinical Trial

NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer

Study acronym: NEODOC
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
This goal of this single arm, single center, exploratory phase I/II clinical trial is to learn more about the immunological efficacy, safety and feasibility of an autologous tumor lysate-loaded autologous XP-DC (cDC1)-based vaccine in patients with ovarian cancer.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-03-06; most recent amendment 2025-11-14.
Status change: Not Yet Recruiting → Recruiting 2023-07-10
Trial Details
NCT Number NCT05773859
Lead Sponsor Radboud University Medical Center
Conditions Epithelial Ovarian Cancer, Ovarian Carcinoma
Enrollment 10 participants
Start Date 2023-03-17
Primary Completion 2026-03 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-18